Bio/Pharma News

Oct 16, 2017
By Pharmaceutical Technology Editors
The new center will serve as a regional hub where scientists and engineers can work with customers for biological development.
Oct 13, 2017
By Pharmaceutical Technology Editors
The committee has voted unanimously to approve Spark Therapeutics’ gene therapy candidate, Luxturna (voretigene neparvovec), for treating a genetically inherited blindness.
Oct 13, 2017
By Pharmaceutical Technology Editors
Baxter and FDA are working together to prevent shortages of the company’s sodium chloride 0.9% injection bags after recent hurricanes damaged the island.
Oct 12, 2017
By Pharmaceutical Technology Editors
NIH has entered a five-year, $215-million collaboration with leading biopharmaceutical companies to advance the development of cancer immunotherapies.
Oct 12, 2017
By Pharmaceutical Technology Editors
The company is investing EUR 170 million (US$201 million) to expand its vaccine manufacturing site in France for its newest influenza vaccine.
Oct 11, 2017
By Pharmaceutical Technology Editors
Johnson & Johnson’s Janssen Sciences Ireland UC will invest more than EUR 300 million (US$355 million) to expand manufacturing capacity for biologic medicines at its Ireland facility.
Oct 11, 2017
By Pharmaceutical Technology Editors
The company is considering options for a full or partial separation of its Consumer Healthcare business, either through a spin-off, sale, or other transaction.
Oct 11, 2017
By Pharmaceutical Technology Editors
Xellia Pharmaceuticals invests US$25 million in its Copenhagen, Denmark site to expand sterile manufacturing of products for treating antimicrobial resistant infections.
Oct 11, 2017
By Pharmaceutical Technology Editors
BARDA has entered a $12-million contract with biopharmaceutical firm Achaogen for the late-stage development of an antibiotic against resistant bacteria, and as a potential treatment for biowarfare agents.
Oct 11, 2017
By Pharmaceutical Technology Editors
AstraZeneca is seeking approval for its anti-cancer monoclonal antibody, Imfinzi, for treating non-small cell lung cancer in the European Union.
native1_300x100
lorem ipsum